drugset
drugset / Trial / NCT02547948

CD19-targeting CAR T Cells for B Cell Lymphoma

NCT02547948 ↗

Phase 1/2 Withdrawn Fuda Cancer Hospital, Guangzhou
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of CD19-targeting CAR T Cells infusion for B Cell Lymphoma.

Timeline

Start
2015-09
Primary completion
2016-08-15
Completion
2016-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD19 CAR-T cells Cell therapy — —

Indications

lymphoma